Scrial No.: 09/528,963

File No.: 31162X

09/464,899, (2) Application Serial No. 09/118,143, and (3) Application Serial No. 08/873,010.

In addition to this claim to priority, Applicant notes that WO98/107771 reference does not include any reference to information concerning the regulation TGF- β , nor does it teach the subject matter in Applicant's claims. The subject matter of applicant's claims is the use of agents with the ability to upregulate TGF- β expression in ovarian epithelial cells whereas the subject matter of WO 98/10771 is to increase apoptosis through the administration of a progestin product. The claims here present a method to test for upregulation of TGF- β in the epithelial cells this subject matter is not obvious from the disclosure of an invention to increase apoptosis through administration of a progestin product.

The examiner also rejected claims 1, 2, 5, and 6 as being indefinite under §112 second paragraph. The Examiner noted that the "term 'regimen' in claim 6 fails to find basis in claims 1, 2, and 5." Applicant has cancelled claim 6 in response thereto.

The examiner also noted that if claim 2 where found allowable, then claims 3-5 would be rejected as being substantial duplicatives thereof. Applicant submits that claims 3-5 are not substantial duplicatives of claim 2 because they are of narrower scope. Specifically claim 3 requires in vivo testing whereas claim 2 is broader because it includes in vivo and in vitro testing. Claim 4 similarly is limited to in vitro testing whereas claim 2 is broader because it includes in vivo and in vitro testing. Claim 5 is limited to TGF-\beta2 or TGF-\beta3, whereas claim 2 does not state any such limitation.

Applicant respectfully submits the pending claims 1-5. Please charge any fees associated with this Response to Deposit Account No. 18-1942.

File No.: 31162X

Serial No.: 09/528,963

Respectfully submitted

Raymond N. Nimrod Registration No. 31,987 Attorney for Applicant Gustavo C. Rodriguez